Curasight

Curasight reported Q2 2026 this morning and, alongside the figures, moved the timing of its three remaining clinical read-outs into 2027, thereby removing some near-term catalysts, but also announced expansions to the Phase I/IIa basket trial.

Curasight announced this morning that it has completed a directed issue of approximately DKK 20m before transaction costs. The issue extends the company's financing horizon. Management now assesses that the net proceeds are sufficient to fund operations through the end of H1 2027.

Curasight this morning announced an encouraging preliminary readout from its Phase 1 trial with uTREAT® in glioblastoma (GBM), This the first of the four high-value data read-outs management guided to for the coming six months.

In connection with Curasight's Q1 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.